Skip to main content

BioLife Solutions, Inc.

corporate_fare Company Profile

BioLife Solutions, Inc.

BLFS·NASDAQ·Industrial Applications And Services·CIK 0000834365

We are a life sciences company that develops, manufactures, and markets bioproduction products and services. These offerings are designed to improve quality and reduce risks in biologic manufacturing, distribution, and transportation within the cell and gene therapy (CGT) industry. Our products are utilized in basic and applied research, as well as in the commercial manufacturing of biologic-based therapies. Customers use our products to maintain the health and function of biologic material during sourcing, manufacturing, and distribution. We currently operate as a single bioproduction products and services business, supporting various steps in the biologic material manufacturing and delivery process. Our portfolio includes biopreservation media and cell processing products. We possess in-house expertise in cryobiology and the broader CGT workflow. On October 6, 2025, the Company entered into a Limited Liability Company Membership Interest Purchase Agreement with Peli BioThermal LLC for the sale of all issued and outstanding limited liability company membership interests of SAVSU Cleo Technologies, LLC. This divestiture included our evo cloud-connected "smart" shipping container products, which provided passive storage and transport for temperature-sensitive biologics and pharmaceuticals. The SAVSU business is presented as a discontinued operation for all periods presented in the accompanying Consolidated Financial Statements. On April 4, 2025, pursuant to a Stock Purchase Agreement, the Company's wholly owned subsidiary, 2699979 Alberta LTD., acquired PanTHERA CryoSolutions Inc.

BioLife Solutions, Inc. (NASDAQ:BLFS) is a publicly traded company in the Industrial Applications And Services sector. Wiseek has independently scored 26 items for BLFS at importance 7 or higher on its 1–10 market-impact scale.

Recent high-impact activity:

  • BioLife Solutions Q1 Revenue Jumps 25% to $27.5M, Reaffirms Full-Year Guidance
  • Officer Sells $1.96M in BioLife Solutions Stock Amid 52-Week Lows
  • BioLife Solutions Issues Investor Presentation with Positive 2026 Revenue Growth Guidance
  • BioLife Solutions Reports Full Year 2025 Results, Details Strategic Portfolio Shifts and Internal Control Remediation
  • BioLife Solutions Reports Strong Q4 & FY25 Results, Guides for 2026 GAAP Profitability

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$96.21M
Net Income
-$4.59M
Diluted EPS
-$0.10
Op. Cash Flow
$20.11M
Free Cash Flow
$10.64M
Gross Profit
$62.12M
Operating Income
-$16.6M
Cash & Equivalents
$33.04M
Total Debt
$5M
Debt / Equity
0.01×
Net Margin
-4.8%
Shares Outstanding
48.2M sh
Source: 10-K · filed 2026-04-28 · accession 0001628280-26-028012

No longer listed

BLFS (BioLife Solutions, Inc.) is no longer listed on a major US exchange, so Wiseek no longer shows market data for this symbol. It last appeared on NASDAQ. BioLife Solutions, Inc was acquired by Repligen Corp (RGEN). The filings and coverage below remain available as an archive.

feed BLFS - Filings & News (Page 2)

BLFS
May 07, 2026, 4:03 PM EDT
Source: Dow Jones Newswires
Importance Score:
8
BLFS
Mar 09, 2026, 6:11 PM EDT
Filing Type: 4
Importance Score:
8
BLFS
Mar 02, 2026, 4:36 PM EST
Filing Type: 8-K
Importance Score:
7
BLFS
Feb 26, 2026, 4:15 PM EST
Filing Type: 10-K
Importance Score:
7
BLFS
Feb 26, 2026, 4:07 PM EST
Filing Type: 8-K
Importance Score:
8
BLFS
Jan 12, 2026, 8:04 AM EST
Filing Type: 8-K
Importance Score:
7
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets